Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUS, SUBCUTANEOUSStandard

RELEUKO

FILGRASTIM-AYOW

Standard Dose
300MCG/ML/VIAL
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Prescription
Summary

Approval overview RELEUKO is listed in Drugs@FDA under application 761082 (BLA).

Marketing status: Prescription Active ingredient FILGRASTIM-AYOW Form and strength SOLUTION;INTRAVENOUS, SUBCUTANEOUS - 300MCG/ML/VIAL Sponsor KASHIV BIOSCIENCES LLC Submission history Latest submission status date: 2025-04-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview RELEUKO is listed in Drugs@FDA under application 761082 (BLA). Marketing status: Prescription Active ingredient FILGRASTIM-AYOW Form and strength SOLUTION;INTRAVENOUS, SUBCUTANEOUS - 300MCG/ML/VIAL Sponsor KASHIV BIOSCIENCES LLC Submission history Latest submission status date: 2025-04-29 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription

Interaction Notes

  • No interaction notes stored yet.
RELEUKO (FILGRASTIM-AYOW) | Drug Monograph | MedicHelpline